Retinoblastoma Vitreous Seed Clouds (Class 3) A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy
被引:29
|
作者:
Francis, Jasmine H.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Weill Cornell Med Ctr, Dept Ophthalmol, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Francis, Jasmine H.
[1
,2
]
Iyer, Saipriya
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Iyer, Saipriya
[1
]
Gobin, Y. Pierre
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Weill Cornell Med Ctr, Dept Neurosurg, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Gobin, Y. Pierre
[1
,3
]
Brodie, Scott E.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Icahn Sch Med Mt Sinai, New York, NY 10029 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Brodie, Scott E.
[1
,4
]
Abramson, David H.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Weill Cornell Med Ctr, Dept Ophthalmol, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
Abramson, David H.
[1
,2
]
机构:
[1] Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Weill Cornell Med Ctr, Dept Ophthalmol, New York, NY USA
[3] Weill Cornell Med Ctr, Dept Neurosurg, New York, NY USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
Purpose: To compare the efficacy and toxicity of treating class 3 retinoblastoma vitreous seeds with ophthalmic artery chemosurgery (OAC) alone versus OAC with intravitreous chemotherapy. Design: Retrospective cohort study. Participants: Forty eyes containing clouds (class 3 vitreous seeds) of 40 retinoblastoma patients (19 treated with OAC alone and 21 treated with OAC plus intravitreous and periocular chemotherapy). Methods: Ocular survival, disease-free survival and time to regression of seeds were estimated with Kaplan-Meier estimates. Ocular toxicity was evaluated by clinical findings and electroretinography: 30-Hz flicker responses were compared at baseline and last follow-up visit. Continuous variables were compared with Student t test, and categorical variables were compared with the Fisher exact test. Main Outcome Measures: Ocular survival, disease-free survival, and time to regression of seeds. Results: There were no disease-or treatment-related deaths and no patient demonstrated externalization of tumor or metastatic disease. There was no significant difference in the age, laterality, disease, or disease status (treatment naive vs. previously treated) between the 2 groups. The time to regression of seeds was significantly shorter for eyes treated with OAC plus intravitreous chemotherapy (5.7 months) compared with eyes treated with OAC alone (14.6 months; P < 0.001). The 18-month Kaplan-Meier estimates of disease-free survival were significantly worse for the OAC alone group: 67.1% (95% confidence interval, 40.9%-83.6%) versus 94.1% (95% confidence interval, 65%-99.1%) for the OAC plus intravitreous chemotherapy group (P = 0.05). The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95% confidence interval, 56.7%-94.3%) for the OAC alone group and 100% for the OAC plus intravitreous chemotherapy group (P = 0.16). The mean change in electroretinography responses was not significantly different between groups, decreasing by 11 mu V for the OAC alone group and 22 mV for the OAC plus intravitreous chemotherapy group (P = 0.4). Conclusions: Treating vitreous seed clouds with OAC and intravitreous and periocular chemotherapy, compared with OAC alone, resulted in a shorter time to regression and was associated with fewer recurrences requiring additional treatment and fewer enucleations. The toxicity to the retina does not seem to be significantly worse in the OAC plus intravitreous chemotherapy group. (C) 2017 by the American Academy of Ophthalmology
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Francis, Jasmine H.
Lyer, Saipriya
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Lyer, Saipriya
Gobin, Pierre
论文数: 0引用数: 0
h-index: 0
机构:
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Gobin, Pierre
Marr, Brian
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Marr, Brian
Brodie, Scott E.
论文数: 0引用数: 0
h-index: 0
机构:
Icahn Sch Med Mt Sinai, New York, NY 10029 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Brodie, Scott E.
Abramson, David H.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol, 1275 York Ave, New York, NY 10021 USA
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA
Abramson, David H.
Dunkel, Ira J.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA
Dunkel, Ira J.
Brodie, Scott E.
论文数: 0引用数: 0
h-index: 0
机构:
Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA
Brodie, Scott E.
Marr, Brian
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA
Marr, Brian
Gobin, Y. Pierre
论文数: 0引用数: 0
h-index: 0
机构:
Weill Cornell Med Coll, Div Intervent Neuroradiol, Dept Radiol Neurosurg & Neurol, New York, NY USAMem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA
机构:
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
Abramson, David H.
Gobin, Y. Pierre
论文数: 0引用数: 0
h-index: 0
机构:
Weill Cornell Med Ctr, Intervent Neuroradiol, New York, NY USAMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
Gobin, Y. Pierre
Dunkel, Ira J.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA
Weill Cornell Med Ctr, Dept Pediat, New York, NY USAMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
Dunkel, Ira J.
Francis, Jasmine H.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
Weill Cornell Med Ctr, New York, NY USAMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA